USP7-797 (USP7-IN-7) is an orally bioavailable, selective USP7 inhibitor (IC50 = 0.5 nmol/L) with antitumor activity; it exerts cytotoxic effects against p53-mutant cancer cell lines, p53 wild-type hematological malignancies, and neuroblastoma cell lines at low nanomolar concentrations by reducing MDM2 levels, thereby enhancing p53 stability and activity, leading to cell cycle arrest and apoptosis.